Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Cash & Current Investments (2024 - 2025)

Evommune (EVMN) has disclosed Cash & Current Investments for 2 consecutive years, with $149.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 107.11% to $149.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.2 million through Dec 2025, up 107.11% year-over-year, with the annual reading at $149.2 million for FY2025, 107.11% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $149.2 million at Evommune, up from $76.1 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $149.2 million in Q4 2025, with the low at $18.1 million in Q3 2024.